ArticleMolecular pharmaceutics2025
Enhanced Drug Loading Capacity Using the Dual Metformine-Dexketoprofren Salt on Nanoapatite Materials.
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both apatite nanoparticles and multicomponent pharmaceutical materials have proved the ability to significantly improve the bioavailability of different drugs using different strategies. Herein, the use of nanoapatite is proposed as a promising vehicle for advanced drug delivery of multicomponent pharmaceutical materials. To this purpose, the full synthesis and comprehensive characterization of apatite nanoparticles and the molecular pharmaceutical salt metformin-dexketoprofen are reported, paying special attention to the improvements regarding solubility and stability of the novel materials compared to the parent active pharmaceutical ingredients, as well as the drug loading capacity enhancement achieved in nanoapatites. Our results evidence the potential of the presented novel strategy, enhancing the dexketoprofen-loading a remarkable 50-fold when compared to native drug, thanks to the improvement of solubility achieved via salt-formation (567 and 168 mg/mL at pH 6.8 and 1.2, respectively), thus expecting improved therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.